[go: up one dir, main page]

SG11202111863RA - Bead-free ex-vivo expansion of human regulatory t cells - Google Patents

Bead-free ex-vivo expansion of human regulatory t cells

Info

Publication number
SG11202111863RA
SG11202111863RA SG11202111863RA SG11202111863RA SG11202111863RA SG 11202111863R A SG11202111863R A SG 11202111863RA SG 11202111863R A SG11202111863R A SG 11202111863RA SG 11202111863R A SG11202111863R A SG 11202111863RA SG 11202111863R A SG11202111863R A SG 11202111863RA
Authority
SG
Singapore
Prior art keywords
bead
cells
free
vivo expansion
human regulatory
Prior art date
Application number
SG11202111863RA
Inventor
Qizhi Tang
Nikolaos Skartsis
Flavio Vincenti
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of SG11202111863RA publication Critical patent/SG11202111863RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202111863RA 2019-04-30 2020-04-30 Bead-free ex-vivo expansion of human regulatory t cells SG11202111863RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841215P 2019-04-30 2019-04-30
PCT/US2020/030869 WO2020223568A1 (en) 2019-04-30 2020-04-30 Bead-free ex-vivo expansion of human regulatory t cells

Publications (1)

Publication Number Publication Date
SG11202111863RA true SG11202111863RA (en) 2021-11-29

Family

ID=73029279

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111863RA SG11202111863RA (en) 2019-04-30 2020-04-30 Bead-free ex-vivo expansion of human regulatory t cells

Country Status (13)

Country Link
US (1) US20220204931A1 (en)
EP (1) EP3963053A4 (en)
JP (2) JP7617023B2 (en)
KR (1) KR20210149201A (en)
CN (1) CN114008192A (en)
AU (1) AU2020266599B2 (en)
BR (1) BR112021021528A2 (en)
CA (1) CA3137456A1 (en)
CL (1) CL2021002849A1 (en)
IL (1) IL287618A (en)
MX (1) MX2021013227A (en)
SG (1) SG11202111863RA (en)
WO (1) WO2020223568A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3238860A1 (en) * 2021-11-24 2023-06-01 Norihisa MIKAMI Pharmaceutical composition for treating or preventing t cell-related disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014201846B2 (en) * 2007-01-30 2016-07-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
WO2012018930A1 (en) * 2010-08-03 2012-02-09 University Of Miami Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy
US9481866B2 (en) * 2011-12-16 2016-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations enriched for stable regulatory T-cells
CN104245923B (en) * 2012-03-02 2018-04-20 加州大学评议会 The propagation of allogenic antigen reactivity regulatory T-cell
EP2660250B1 (en) * 2012-05-02 2018-11-14 Deutsches Rheuma-Forschungszentrum Berlin Tcr transgenic mouse model for immune disease
PL218400B1 (en) * 2012-06-06 2014-11-28 Gdański Univ Medyczny A vaccine for the treatment of type 1 diabetes in children, the use of a cell sorter and a method for proliferation of Treg cells producing a vaccine for the treatment of type 1 diabetes
WO2014165581A1 (en) * 2013-04-02 2014-10-09 New York University Gpr15-mediated homing and uses thereof
EP3131559B1 (en) * 2014-04-16 2019-02-13 Genovie AB Cd8+ regulatory t-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract
US20170198044A1 (en) * 2014-06-23 2017-07-13 Theramab Llc Compositions and methods for safe and effective immunotherapy
WO2016179288A1 (en) * 2015-05-04 2016-11-10 University Of Florida Research Foundation, Inc. Novel regulatory-cells, method for their isolation and uses
HK1255101A1 (en) 2015-07-03 2019-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for obtaining regulatory t cells and uses thereof
CN108291203A (en) * 2015-09-07 2018-07-17 国家健康科学研究所 The new subgroup and application thereof of the low TREG of CD8+CD45RC

Also Published As

Publication number Publication date
BR112021021528A2 (en) 2022-04-19
CL2021002849A1 (en) 2022-11-25
JP7617023B2 (en) 2025-01-17
AU2020266599A1 (en) 2021-11-18
AU2020266599B2 (en) 2025-10-02
IL287618A (en) 2021-12-01
EP3963053A1 (en) 2022-03-09
JP2025072363A (en) 2025-05-09
JP2022530768A (en) 2022-07-01
CA3137456A1 (en) 2020-11-05
US20220204931A1 (en) 2022-06-30
EP3963053A4 (en) 2023-01-18
CN114008192A (en) 2022-02-01
KR20210149201A (en) 2021-12-08
WO2020223568A1 (en) 2020-11-05
MX2021013227A (en) 2022-01-06

Similar Documents

Publication Publication Date Title
ZA202105970B (en) Novel heterotricyclic derivative compound and use of same
SG11202011191WA (en) Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
ZA202007701B (en) Triesters of cyclohexanetripropionic acid
PL3830085T3 (en) Deuterated derivatives of lanifibranor
IL271159A (en) Synthesis of substantially diastereomerically pure phosphate protides
IL291622A (en) Compositions comprising regulatory t cells and methods of making and using the same
IL274436B1 (en) Preparations for the production of islet cells and methods of use
EP4041386A4 (en) Wet preparation of radiotherapy sources
RS63966B1 (en) INDUSTRIAL PROCEDURE FOR THE PREPARATION OF HIGH PURITY ESTETROL
IL276592A (en) Derivatives of sobetirome
SG11202101671PA (en) Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
SG11202103901YA (en) Expansion of hematopoietic stem cells
EP3942503A4 (en) Multi-axis blockchain clearance of offers
IL287618A (en) Bead-free ex-vivo expansion of human regulatory t cells
EP3836935A4 (en) Treatment of b cell malignancies
GB202213340D0 (en) Stem cell line for treatment of various medical conditions
GB202103774D0 (en) Detectiion of Ransomware
EP3362044A4 (en) Treatment for infection composed of menstrual stem cells
HK40069526A (en) Bead-free ex-vivo expansion of human regulatory t cells
PL3570661T3 (en) Procedure for the cultivation of mushrooms
ZA202105399B (en) Use of spiropidion
GB201911056D0 (en) Treatment of ADD/ADHD
GB201821321D0 (en) Expansion of T cells
GB201917015D0 (en) Provision of interlinked system
HK40080108A (en) Generation of engineered regulatory t cells